Our study presents a novel therapeutic strategy for targeting autophagy-mediated resistance in pancreatic cancer and lays the groundwork for its application in other resistant cancer types, given that prior studies have also determined that targeting VCP can also sensitize cells to cisplatin and other treatments [74]. This evidence concerns the gene VCP and familial pancreatic carcinoma.